drugset / Trial / NCT01127906

Study To Assess The Effect Of PF-04531083 On Heat Pain In Healthy Volunteers With Ultraviolet Light Sensitized Skin

NCT01127906

Phase 1 Completed 36 enrolled Pfizer
RandomizedCrossoverQuadruple-blindBasic science

Summary

PF-04531083 has been shown to reduce the amount of heat pain experienced by rats with skin that has been sensitized to heat by ultraviolet light. This study is designed to see if this is also true in man.

Timeline

Start
2010-06
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxycodone Other / unclassified 20 mg Oral
Subject PF-04531083 Small molecule 100 mg Oral
Subject PF-04531083 Small molecule 2000 mg Oral

Indications

No indication recorded.